// App-Quantinova.ai

3252 : Engineered human IL-2/IL-2Rb orthogonal pairs selectively enhance CAR T cell anti-tumor efficacy and durability of response

Researchers

Presenter

  • Paul-Joseph Aspuria

Principal Investigators

  • Michele Bauer

  • Sandro Vivona

  • Steven E. Kauder

  • Scott McCauley

  • Romina Riener

  • Rene De Waal Malefyte

  • Navneet Ratti

  • Deepti Rokkam

  • Jan Emmerich

  • Patrick J. Lupardus

  • Rob A. Kastelein

  • Martin Oft

Medical Centers

  • Synthekine, Menlo Park, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Hematological malignancies

  • Non-Hodgkin's Lymphoma

  • Non‐Hodgkin Lymphoma

  • Hodgkin's Lymphoma

  • Lymphomas

Biomarkers

  • Natural Killer cells

  • Breakpoint Cluster Region

  • Cluster of Differentiation 19

  • Cluster of Differentiation 4

  • Cluster of differentiation 8A

  • Coxsackie Virus And Adenovirus Receptor

  • Granzyme B

  • Interleukin-2

Drug/Treatment

  • Interleukin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved